Trump’s Drug Pricing Push Now Covers 89 Percent of Branded Market
President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.
How this was made
The 30-second read
Why it matters
The policy aims to lower Medicaid drug costs but may compress margins for participating firms, while the pledged manufacturing investments could support U.S. supply chains.
Market read
Policy change creates immediate pricing risk for a broad set of pharma stocks, with potential longer‑term benefits from domestic manufacturing commitments.
What to watch
The $19.6 billion manufacturing investment commitment could offset pricing impacts for participating companies.
Background
The Trump administration expanded its Most‑Favored‑Nation drug‑pricing initiative, adding nine pharmaceutical companies to cover 89% of the branded market.
Ticker impact
Alcon joined the MFN pricing program covering 89% of the branded market.
Modest downside risk if Medicaid pricing reduces revenue.
Policy change affects pricing but impact depends on volume of Medicaid sales.
BridgeBio entered the MFN drug‑pricing initiative.
Limited downside as company is small‑cap.
Effect limited by BridgeBio's modest U.S. sales.
Teva Pharmaceuticals committed to MFN pricing for Medicaid.
Moderate downside pressure.
Teva has sizable U.S. generic portfolio.
UCB joined the MFN pricing push, covering 89% of branded market.
Modest negative impact.
UCB's U.S. specialty drugs will be subject to MFN pricing.
Market effects
Broad impact on U.S. pharmaceutical pricing and Medicaid reimbursement expectations.
U.S. healthcare sector may see margin compression; global pharma firms with U.S. exposure could be affected.
Sets precedent for future drug‑pricing negotiations worldwide.
Counterpoint
Some investors may view the MFN program as a catalyst for consolidation, benefiting larger firms that can absorb pricing pressure.
Key entities
- political figureDonald Trump
President announcing the MFN expansion.
- government officialRobert F. Kennedy Jr.
HHS Secretary highlighting the program's scope.
